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Abstract.  TGF-/3 is a potent stimulator of motility in 
a variety of cell types. It has recently been shown that 
hyaluronan (HA) can directly promote locomotion of 
cells through interaction with the HA receptor 
RHAMM. We have investigated the role of RHAMM 
and HA in TGF-/3-stimulated locomotion and show 
that TGF-B triggers the transcription,  synthesis and 
membrane expression of the RHAMM receptor and 
the secretion of HA coincident with the induction of 
the locomotory response. This was demonstrated by 
both incubating cells with exogenous TGF-Bt  and by 
stimulating the production of bioactive TGF-/3~ in tu- 
mor cells transfected with TGF-B~ under the control of 
the metallothionein promoter.  TGF-/31-induced loco- 
motion was suppressed by antibodies that prevented 
HA/RI-IAMM interaction,  using polyclonal antibodies 
to either RHAMM fusion protein or RHAMM pep- 
tides, or mAbs to purified RHAMM. Peptides corre- 
sponding to the HA-binding motif of RHAMM also 
suppressed TGF-B,-induced increases in motility rate. 
Spontaneous locomotion of fibrosarcoma cells was 
blocked by neutralizing  secreted TGF-~/with 
panspecific TGF-/3 antibodies and by inhibition of 
TGF-/3~ secretion with antisense oligonucleotides. 
Polyclonal anti-RHAMM fusion protein antibodies 
and peptide from the RHAMM HA-binding motif also 
suppressed the spontaneous motility rate of fibrosar- 
coma cells. These data suggest that fibrosarcoma cell 
locomotion requires TGF-/3, and the pathway by which 
TGF-~/stimulates locomotion uses the HA receptor 
RHAMM and HA. 
THOUGH the factors that control cell locomotion are 
poorly understood, it is becoming clear that  some 
ceils  can  produce  autocrine  motility  factors  and 
cytokines (Liotta and Schiffman,  1988;  Stoker and Gber- 
ardi,  1991) through  which they regulate chemokinesis and 
chemotaxis.  Transforming  growth factor betas (TGF-/~s)~, 
of which there are three manunalian  isoforms,  are 25-kD 
homodimeric peptides that act as multifunctional  regulators 
of mesenchymal, endothelial,  and epithelial  cells (Roberts 
and Sporn,  1989;  Bamard et al.,  1990;  Massagu6 et al., 
1990). TGF-B has been implicated in a variety of physiologi- 
cal and pathological  processes in which cell locomotion is 
essential such as embryogenesis (Heine et al., 1987), wound 
repair  (Pierce et  al.,  1989),  inflammation  (Allen  et al., 
1990; Khalil et al., 1990, 1991), and tumor invasion (Welsh 
et al.,  1991; McCarthy and Turley,  1992;  Samuel et al., 
1992). 
TGF-B1 in  its  role  as  a  regulator  of cell  motility  is  a 
powerful chemoattractant that promotes both chemokinesis 
and chemotaxis in a variety of cell types (Posflethwaite et al., 
1. Abbreviations  used in this paper: DM, defined medium; ECL, enhanced 
chemiluminescence,  GAPDH,  glyceraldehyde-3-phosphate  dehydroge- 
nase; HA, hyaluronan; TGF-13, transforming growth factor beta. 
1987; Wahl et al., 1987; Reibman et al., 1991; Samuel et al., 
1992). In neutrophils and maerophages,  TGF-B has been ob- 
served to be a potent chemoattractant (Wahl et al.,  1987; 
Fava et al., 1991; Riebman et al., 1991), and it has been sug- 
gested that  the chemotactic potency of TGF-B for macro- 
phages may be relevant for diseases that are characterized by 
inflammation and fibrosis (Khalil and Greenberg, 1991; Fava 
et al.,  1991). TGF-/3 may be involved in the initial  recruit- 
ment of macrophages  and the migration of fibroblasts  seen 
in these lesions.  Posflethwaite and co-workers (1987) have 
shown that picogram levels of TGF-B1 are sufficient to en- 
hance chemokinesis  and chemotaxis of normal fibroblasts. 
While  the  mechanism  through  which  TGF-/3 regulates 
locomotion is poorly understood, studies in neutrophils indi- 
cate that TGF-/51 triggers protein synthesis and actin assem- 
bly that are required for chemotaxis but, unlike conventional 
ebemoattractants,  it does not act via common signal trans- 
duction pathways (Riebman et al., 1991). In many cell types, 
TGF-B promotes hyaluronan  (HA) synthesis  (Toole et al., 
1989;  Heldin  et  al.,  1989),  while  HA  is  important  in 
fibrosarcoma cell locomotion following  transformation  by 
H-ms (Turley et al., 1991) and in mammary carcinoma cell 
locomotion (Schor et al., 1989). HA is a repeating disaccha- 
ride of N-acetyl-glucosamine and o-glucuronic acid that is 
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lates at sites of embryonic call migration (for review see 
Toole et al.,  1989),  and coincides with the appearance of 
macrophages and fibroblasts in wound repair responses in 
the lung (Bray et al.,  1991; Nettelbladt et al.,  1989).  In- 
creased synthesis of HA is seen in melanoma and carcinoma 
cell lines both in vivo and in vitro, and HA synthesis corre- 
lates with increased invasiveness and metastatic ability of 
these tumors (Turley and Tretiak, 1985; Kimata et al., 1983; 
Toole et al., 1979). HA can directly promote locomotion and 
accumulates in the extending lamellae of  motile cells (Turley 
et  al.,  1991). Several  HA  binding  proteins  have  been 
identified but only two cell membrane receptors, CD44 and 
RHAMM, have been cloned (for reviews  see Toole,  1990; 
Turley,  1991). Recently, we have shown that the production 
of RHAMM and HA is required for tumor cell locomotion 
(Hardwick et al.,  1992).  RHAMM, a 58-kD glycoprotein, 
is a novel HA receptor that bears no primary sequence ho- 
mology to other known HA-binding proteins. RHAMM ac- 
cumulates at the tips of advancing lamellipodia in locomot- 
ing cells and polyclonal antibodies directed to peptides of  the 
deduced amino acid sequence block HA-stimulated locomo- 
tion (Hardwick et al.,  1992).  In the present study, we have 
examined the mechanism by which TGF-/3 stimulates loco- 
motion and show that HA/RHAMM signalling is required 
for cell motility. 
Materials and Methods 
Cell Lines 
The properties of the C1, C3, and C17.18 cell lines have been described pre- 
viously (Samuel et al., 1992). In brief, C1 and C3 were obtained when the 
parental 101"1/2 fibroblasts were transfected with a plasmid which contains 
the 6.6-kb  fragment of T-24-H-ras  and neo  R gene.  C17.18 was obtained 
when the parental C1 fibroblasts were transfected with pPK9A, which con- 
tained a complete TGF-Ot eDNA under the control of the metallothionein 
promoter. Furthermore, this eDNA was subjected to site-directed mntagen- 
esis of cysteines 223 and 225 in the propeptide in order to allow for secretion 
of bioactive TGF-~I (Samuel et al.,  1992). All cell lines were maintained 
at 37°C on 150 nun plastic tissue culture plates (Falcon Plastics,  Cockeys- 
ville, MD) in culture medium containing c~-MEM  (Flow Laboratories, Mis- 
sissanga,  Ontario) supplemented with antibiotics and 10% (vol/vol) FCS 
(GIBCO BRL, Gaithersburg, MD). A serum-free medium called defined 
medium (DM) was also used which contained 4.0 ttg/ml transferrin and 2.0 
/~g/ml insulin in c~-MEM. 
Antibodies 
Panspecific  neutralizing anti-TGF-/~ antibody (R&D Systems,  Inc., Min- 
neapolis,  MN) was used at a concentration of 500/~g/ml as suggested by 
the manufacturer.  Monoclonal and polyclonal antibodies to RHAMM used 
in this study have been described previously  (Turley and Torrance,  1985; 
Turley et al.,  1987; Turley et al.,  1991; Hardwick et al.,  1992). The anti- 
bodies include routine monoclonals MSV 10-4 and 10-6 that were raised 
against purified RHAMM protein, rabbit anti-RI-IAMM  peptide  aa266-2ss 
(R3.2), and rabbit anti-RHAMM fusion protein antibody all of which can 
block HA-mediated locomotion.  Rabbit anti-RHAMM peptide aat24-145 an- 
tibody, which did not block locomotion, and normal murine IgG served as 
controls. 
Northern Blotting 
Cells were plated onto  150 mm tissue culture plates containing 10 ml 
c~-MEM  (Flow  Laboratories)  supplemented with  antibiotics and  10% 
(vol/vol) FBS (Hyclone Laboratories, Logan,  UT). At ,'~90% confluence, 
cells were washed with Hanks medium and 2.0 ml of phosphate buffered 
0.1% trypsin-EDTA solution was added.  Cells were subsequently  cultured 
in DM. At ~60% confluence,  C3 cells were exogenously  stimulated with 
TGF-~l  (10 ng/ml) (R & D Systems, Inc.) or its secretion induced by the 
addition of zinc sulfate (100 ~tM) to cultures of C17.18. After appropriate 
incubation times, cells were washed with PBS (three times) and then re- 
moved with trypsin solution.  A rapid RNA extraction method was used to 
prepare total cellular RNA (Gough,  1988),  which was subjected to elec- 
trophoresis through 1% formaldehyde-agarose gels followed by transfer to 
Nytran nylon membranes (Schleicher and Schuell, Keene, NH). Blots were 
prehybridized and hybridized as described previously  (McClarty et ai., 
1987; Hurta et al., 1990, using a 32p-labeled 1.9-kb EcoRI fragment from 
the RHAMM cDNA containing plasmid DHI (Hardwick et al.,  1992). 
Blots were washed, and autoradingraphy was performed as previously de- 
scribed (Hurta et al.,  1991). Loading was monitored with a plasmid con- 
taining  the  glyceraldehyde-3-phosphate  dehydrogenase  gene  (GAPDH) 
labeled by nick translation. Densitometric analysis of appropriate autora- 
diograms was carried out using a gel scanning spectrophotometer (DU-8; 
Beckman Instruments, Palo Alto, CA) and the one-dimensional Bio-Rad 
program (Bio-Rad Laboratories, Cambridge,  MA). 
Western Blot Assays 
Western blot analyses were conducted using lysates of C3 and C17.18 fibro- 
blasts prepared by treating cells with lysis buffer containing 25 mM Tris, 
0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, 0.15 M NaC1, I mM 
EDTA, and protease inhibitors (Turley et al., 1987). Proteins were resolved 
on 10% SDS-PAGE gels (Laemmli, 1970) and transferred to nitrocellulose 
membranes at 175 V for 1 h at 15°C. The nitrocellulose  was blocked by 
incubation for I h with 5% nonfat powdered milk in TBS (20 mM Tris, 130 
mM NaCI, pH 7.4) and incubated with primary antibody (R3.2;  1:1,000 di- 
lution in TBS containing 0.05% Tween-20 and 1% skim milk) for 12 h at 
4°C on a gyratory shaker. The blot was then washed three times (10 rain) 
with  TBS  containing 0.05%  Tween-20  (TTBS),  incubated with  HRP- 
conjugated goat anti-rabbit  IgG (1:5,000 in TTBS containing 1% skim milk) 
for 1 h, and then washed with TTBS.  Blotting  was visualized  by the en- 
hanced  chemiluminescence  (ECL)  Western  blotting  detection  system 
(Amersham, Mississauga,  Ontario) foliowing  manufacturers'  directions. 
Quantitation was performed on a videodensitometer (model 620; Bio-Rad 
Laboratories). 
Cellular Immunofluorescene and Flow Cytometry 
C3 and C17.18 fibroblasts were cultured in 10% FCS and then switched to 
defined medium for between three and eight cell divisions before initiating 
treatment with either TGF-~I or ZnSO4. After stimulation for defined time 
periods, the cells were lifted from the petri dishes using 2.5 mM EDTA in 
HBSS and washed once with I-IBSS (GIBCO-BRL)  containing 10% FCS. 
The viability of cells was determined by Trypan blue exclusion and was be- 
tween 85 and 90%. An aliquot of 2  ×  106 cells was then incubated with 
a  1/50  dilution of R3.2  antibody to  peptide  268-288  encoded  in  the 
RHAMM eDNA (Hardwick et al.,  1992) in a total volume of 200/~1 of 
HBSS/10% FCS for 30 min on ice. At the end of the incubation, the cells 
were washed once in cold HBSS/10% FCS and resuspended in a 1/100 dilu- 
tion of fluorescein-conjugated  goat anti-rabbit IgG antibody (Sigma Im- 
munochemicals, St. Louis, MO) in the same buffer, incubated, and washed 
as above. The cells were then fixed in 400 ~tl of 1% paraformaldehyde  in 
PBS and analyzed using an EPICS Model 753 flow cytometer (model 753; 
Epics,  Inc., New York) (500 mW, 488 nm). Fluorescence was detected at 
525 nm. Forward and 90  ° light scarer measurements were used to establish 
gates for intact, viable fibroblasts. Single parameter, 255 channel, log inte- 
gral green fluorescent  histograms were obtained, each based on 5  ×  103 
gated events. 
Membrane immunofluorescence  of C3 and C17.18 cells for photomicrog- 
raphy was performed as described in our earlier publications (Turley and 
Torrance,  1985; Tarley and Auersperg,  1989) using the R3.2 polyclonal an- 
tibody to peptide  ~ts-2ss of RI-IAMM. Monolayers  were fixed in freshly 
prepared 3 % paraformaldehyde  for 10 min. Fixed monolayers were then in- 
cubated  with  antibody  (1:40  dilution in  PBS)  overnight  at  4°C.  The 
monolayers were again washed then incubated with fluorescein-labeled  goat 
anti-rabbit IgG  (1:1,000 dilution in PBS).  Processed monolayers  were 
viewed with a Zeiss IM35 microscope (Carl Zeiss, Oberkochen, Germany) 
equipped with epifluorescence using nonoverlapping filters of 450--490 nm. 
Cell Motility Analysis 
An image analysis system capable of quantifying cell motility as nuclear dis- 
placement from a sequence of digitalized  or time-lapsed  images was used 
(Image  1; Universal Imaging Corporation, Westefiester, PA). Aliquots of 
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Cell lines were cultured in 150 mm tissue culture plates (Falcon Laborato- 
ries) with DM at 37°C with or without TGF-~/I. At appropriate time inter- 
vals, this conditioned medium was removed, centrifuged to remove cell de- 
bris, placed in siliconized polypropylene tubes with protease inhibitors and 
then frozen at -80°C as described by Danielpour et al. (1988). Conditioned 
medium obtained from above-mentioned cell lines was used to quantitate 
the amount of HA being secreted by C3 and C17.18 with or without TGF- 
Bl. This was done by using the Pharmacia HA Test (Pharmacia, Sweden) 
according to manufacturers' directions. 
Antisense Oligonucleotides 
Phosphorothioate oligodeoxynucleotides were prepared on a  DNA  syn- 
thesizer (380B;  ABI Adv.  Biotechnologies, Inc.,  Columbia,  MD).  Se- 
quences used  were as  follows:  TGF-/~] antisense,  CGGA~TAC- 
GC_K~GC~A where only  the  sequence GGGCK;TACG  used phosphoro- 
thioates and the remaining bases were phosphodiesters; TGF-/~  sense, 
GCCTCCCCCATGCGC~CCT  where only the sequence CCCCCA'IGC 
used  phosphorothioates.  This  mixture  of phosphorothioates and  phos- 
phodiesters was the most effective and least toxic of the sequences that we 
evaluated. The oligonucleotides were added directly to subconfluent cells 
at the indicated times. 
Peptides of the Hyaluronan Binding Domains 
A peptide corresponding to one of the HA binding domains of RHAMM 
(Yang et al.,  1993)  was prepared on a peptide synthesizer (Applied Bio- 
systems,  Foster  City,  CA).  The  peptide  from  the  second  domain  of 
RHAMM  at  amino  acids  423-432 (KLRSQLVKRK)  or  randomized pep- 
tide  '.23432 (QSKRLKKRVL) were added directly to subconfluent cells at a 
concentration of 10 ttg/ml in the presence or absence of TGF-~. 
Results 
Time (hours) 
Induction of  Locomotion by TGF-B, 
The  rate  of locomotion of subconfluent  C3  fibrosarcoma 
ceUs was determined by timelapse image analysis of random 
locomotion at increasing concentrations of TGF-B, in serum- 
free DM. We observed a maximal rate of C3 locomotion in 
the presence of TGF-B~ between 3 and 10 ng/ml (Fig.  1 A), 
from 5 to 11 h after addition of TGF-~/~ to culture medium 
(Fig.  1 B).  At 30 ng/ml and higher,  locomotion decreased 
(Fig.  1 A). No discernible increases in rates of locomotion 
over the controls were observed at the lower concentrations 
of TGF-/3,  (0.1-0.5 ng/ml). Cells cultured in 10 ng/ml TGF- 
~  increased then decreased their motility rate with time af- 
ter subculture so that locomotion had dropped to the rate of 
cells incubated without TGF-~/by 24 h, but not to the initial 
locomotion  rate  (Fig.  1 B).  Without  added  TGF-~/~, the 
motility rate increased progressively over 24 h to 26/~m/min 
or 2.4-fold over the rate measured within the first 2 h of plat- 
ing the cells (Fig.  1 B). 
To  determine  whether  TGF-~  could  induce  motility 
through autocrine stimulation, we also examined the C17.18 
fibrosarcoma cells, which were transfected with an expres- 
sion vector in which the complete coding region of TGF-~h 
was  placed under  the  control  of the metallothionein pro- 
moter (Samuel et al.,  1992).  Cys 223 and 225 in the TGF- 
B~ propeptide had been converted to serines, mutations that 
result in dissociation of the propeptide and secretion of bio- 
active TGF-B]  (Samuel et al.,  1992).  After zinc  sulphate 
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5  ×  103  cells were placed onto a  25  cm  2 tissue culture flask (Falcon 
Laboratories) and cultured as described above. Cells were tracked 24-h af- 
ter subculturing every 10 rain for 27 h and a minimum of 30 cells were ex- 
amined in each experiment. 
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Figure 1. Locomotion rate of TGF-#l-stimulated cell lines. (A) C3 
fibrosarcoma cells were subcultured and at 50 to 75 % confluence 
TGF-/3~ was added at the doses indicated. Time lapse image analy- 
sis recorded the motility rate of 30 cells at 2- (=) and 5-h (zx) inter- 
vals. (B) Locomotion rate of C3 cells incubated in 10 ng/ml TGF- 
#~ (a) or control  medium (zx) over 27 h of image recording.  (C) 
C17.18 has been transfected with the plasmid pPK9A that contains 
the complete open reading frame of 'IGF-#~ with cysteine to ser- 
ine mutations in positions 223 and 225 of the propeptide, and is un- 
der the control of the metallothionein  promoter.  The addition of 
ZnSO4 to the culture medium induces synthesis and secretion of 
bioactive TGF-/~ within 2 h (Samuel et al., 1992). Image analysis 
of locomotion rates were recorded at time intervals following addi- 
tion of 100 #M ZnSO4 or diluent to the culture medium of sub- 
confluent cells. 
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sixfold  and  bioactive  TGF-/3  was  increased  9-  to ~  14-fold 
(Samuel et al., 1992). This cell line also became more motile 
after addition  of ZnSO4  to  subconfluent  monolayers with 
increased locomotion detected as early as 2 h after TGF-/3~ 
induction.  Motility rates reached maximal levels by 8-10 h 
(Fig.  1 C). 
RHAMM and Hyaluronan Synthesis Are Stimulated 
by  TGF-/3, 
It has previously been shown  that  TGF-/~t increased HA 
production (Toole  et  al.,  1989, Heldin et  al.,  1989),  and  HA 
could itself mediate locomotion through an interaction with 
the HA receptor RHAMM (Turley, 1991).  We examined the 
regulation  of  RHAMM  and  HA  by  TGF-/3~ using  sub- 
confluent C3 cells cultured in defined medium in the pres- 
ence  or  absence  of TGF-/31. At  designed  time  intervals, 
both mRNA  and  cell protein  samples were prepared.  In- 
creased RHAMM mRNA levels were seen as early as 2 h 
after TGF-/3 stimulation (Fig. 2 A). Total cellular RHAMM 
protein was elevated in cells exposed to 3 to 30 ng/ml TGF- 
/31 with maximal response occurring  at a  concentration of 
10 ng/ml for 8 h (Fig. 2 B), which was similar to the locomo- 
tory response to TGF-/31 (Fig.  1,  A  and B).  Over a  24-h 
time course, increased RHAMM protein expression was first 
detected  1 h  after stimulation with TGF-/3t  rising to near 
maximum levels by 4 h. A gradual but much smaller increase 
in RHAMM expression was also observed in C3 cells cul- 
tured without added TGF-/3~ reaching maximal expression 
at 24 h relative to controls at the initiation of the culture (Fig. 
2  C).  Induction  of TGF-/3~ secretion by ZnSO4  in  C17.18 
also resulted in an elevation in RHAMM mRNA expression 
(Fig.  3 A) for up to 8  h  poststimulation which diminished 
somewhat at  later  times.  RHAMM  mRNA  in  uninduced 
C17.18 cells was essentially unchanged over 24 h of culture. 
Corresponding  changes  in protein levels were detected  in 
ZnSO4-induced  cells,  with  maximal  RHAMM  expression 
fivefold over controls by 8-h postinduction  (Fig.  3 B). 
Figure 2.  RHAMM mRNA and protein synthesis is enhanced by 
TGF-/~. C3 cells were incubated in TGF-~ and RHAMM mRNA 
or protein  levels were determined  as described  in methods.  (A) 
Northern analysis was conducted on ceils incubated in I0 ng/ml of 
TGF-/3L at the times indicated.  (B) Cells  incubated in increasing 
concentrations of TGF43~ were analyzed by Western blotting after 
8 h. (C) C3 cells were incubated in 10 ng/ml TGF-/31 and sampled 
at the times for Western analysis. GAPDH is shown in (A) as a con- 
trol for RNA loading. 
Figure 3.  Autocrine stimulation of RHAMM mRNA and protein 
synthesis  following activation  of TGF-/3~ secretion.  C17.18 was 
stimulated with 100 ttM ZnSO4 and RHAMM RNA (A) and pro- 
tein (B) levels were determined  at the indicated  time intervals. 
GAPDH was used as a loading control. 
The Journal of Cell Biology, Volume 123, 1993  752 Figure 4. TGF-fl~ increases RHAMM expression on the cell membrane.  (A) C3 cells were incubated with (solid lines) or without (dashed 
lines)  10 ng/ml TGF-fll, and C17.18 cells were incubated in the presence  (solid lines) or absence (dashed lines) of 100 #M ZnSO4 for 
the  time periods  indicated.  The  cells  were  stained  with  rabbit  anti-RHAMM  peptide  26s-2s8 antibody  and  fluorescein-labeled  goat 
anti-rabbit antibody, then analyzed on a Coulter counter (Epics, Inc.) as described in Materials and Methods. All experiments included 
two controls which were not significantly different from the time 0 h in cells treated with anti-RHAMM peptide 26s-288 antibody; normal 
IgG as first antibody, and fluorescent second antibody alone. (B) C3 and C17.18 cells were incubated and stained as described in A. Shown 
are fluorescence photomicrographs  of the cells following 8 h of stimulation or controls  incubated for an equivalent period  in medium. 
Increased RHAMM protein was detected on the cell sur- 
face by flow cytometry within 2 to 4  h after TGF-fll stimu- 
lation of C3 cells or ZnSO4 treatment of C17.18 cells using 
a polyclonal rabbit anti-RHAMM peptide 268-288 antibody 
and  fluoresceinated  goat anti-rabbit  antibody  (Fig.  4  A). 
Peak expression was reached between  8  and 24  h,  corre- 
sponding  to  the  times  noted  for  maximal  production  of 
RHAMM protein as detected by immunoblot assays (Figs. 
2 C and 3 B). Fluorescent photomicrography of cells stimu- 
lated for 8 h confirmed that most of the RHAMM protein was 
expressed at the cell surface (Fig.  4  B). 
C3 cells synthesized and released HA into the medium in 
large amounts when cultured in  10 ng/ml TGF-fl~.  A  tran- 
sient increase in HA secretion in both TGF-fl~-treated cells 
and control was seen in the first 2 h of culture. However, the 
untreated  control  C3  cells  gradually  decreased  secretion, 
while TGF-Brtreated cells continued to produce HA at a 
relatively stable level thereafter of about 1/~g/ml (Fig. 5 A). 
Increased HA secretion by C17.18 was also observed after 
TGF-fl~ induction by ZnSO4 and remained higher than con- 
trois over the next 24 h  (Fig.  5 B). 
Inhibition of CeU Motility with Anti-TGF-fl Antibody 
and Anti-Sense TGF-flt Oligonucleotides 
C3  cells  secrete  increased  amounts  of bioactive  TGF-fl~ 
(Schwarz  et al.,  1990).  The hypothesis that  this  secreted 
TGF-fl~  autostimulates  locomotion  was  tested  by  treating 
C3 cells in subconfluent culture with a panspecific TGF-fl 
neutralizing antibody (500 ttg/ml). A  90% reduction in the 
rate of locomotion was  observed within  5  h  and  then re- 
mained very low over the next 20 h (Fig. 6). This antibody 
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1000  _.  antisense  oligonucleotides  reduced  TGF-~  secretion  to  / 
1~/~  about 50% of sense and untreated controls (Fig. 7), which 
was about equivalent to the inhibition of cell locomotion. 
$"  Inhibition of TGF-[31-lnduced  Locomotion by 
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We hypothesized that the TGF-/3~-induced locomotion was 
mediated through HA stimulation of the RHAMM receptor. 
To test this directly, we used a panel of monoclonal anti- 
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Figure 5. TGF-~/] stimulates HA synthesis in locomoting cells. Af- 
ter subculture, C3 cells (A) were cultured in TGF-Bx and culture 
medium sampled at the time intervals indicated. TGF-Bt secretion 
in C17.18 cells (B) was initiated with ZnSO4 and medium assayed 
for hyaluronan at increasing time in culture. Conditions were iden- 
tical to those used to induce cell locomotion shown in Fig.  1. 
was also able to significantly decrease locomotion when it 
was added to cultures of C3 cells containing 3 ng/ml TGF- 
fll (not shown). 
To further test this hypothesis, an anti-sense TGF-/3~ oli- 
gonucleotide was synthesized based on the murine TGF-fl~ 
sequence spanning the initiation codon from -9 to +10 (see 
Materials and Methods). Either the antisense or sense oligo- 
nucleotide was added at a concentration of 0.8 #M to sub- 
confluent C3  cells.  A  decrease in locomotion of 45%  of 
sense or untreated controls was observed by 8 to 10 h (Fig. 
7).  Examination of culture supernatants indicated that the 
(268-288) and anti-RHAMM fusion protein polyclonal anti- 
body, which have been shown to inhibit HA-induced loco- 
motion (Turley et al.,  1991; Hardwick et al.,  1992). Anti- 
body or normal IgG was added to subconfluent C3 cells after 
8 h of stimulation with 10 ng/ml TGF-/% Before the addi- 
tion of antibody, C3 locomotion progressively increased to 
an average velocity of 46.9  5=  1.9/~m/min. Within 30 min 
of the addition of 1/~g/ml of either RHAMM monoclonal or 
polyclonal antibodies, a reduction in the rates of locomotion 
to between 3.66 +  0.8 and 11.09 +  1.4 ftm/rnin (Fig. 8) was 
observed, with the polyclonal anti-RHAMM fusion protein 
antibody being the most effective. Controls included normal 
mouse IgG and polyclonal anti-RHAMM peptide 124-145 
antibody,  which  do  not  block  HA-induced  locomotion 
(Hardwick  et al.,  1992).  Identical results  were obtained 
when  ZnSO4-stimulated  C17.18 cells  were  treated  with 
these antibodies (not shown). 
We observed that C3  cells in culture in the absence of 
added TGF-/~ progressively increased locomotion (Fig. 1 A) 
as well as RHAMM protein expression (Fig. 2 C). This in- 
crease  may  have  been  due  to  autocdne  stimulation  of 
RHAMM as a result of the ~nthesis and secretion of TGF- 
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30  ~  .-,  secretion  with  TGF-fl,  anti- 
x=  sense  oligonucleotides.  C3 
25  ~  cells treated for 8 h with 0.8 #M 
o  of anti-sense TGF-fl, or sense 
20  ~  TGF-fll  oligonucleotides  or 
=  left  untreated.  Anti-sense 
15  ~  (CGGAGGGGGTACGGC- 
10  j+  CGGA) and sense (GCCTCC- 
.~  CCCATGCGGCCCT) oligo- 
5  ~  m  nucleotide  sequences  were 
taken from the -9 to + 10 po- 
0  sitions spanning the initiation 
codon  of TGF-flb  Locomo- 
tion  rate (+SE)  was tracked 
by image analysis on 30 cells in each condition. Culture supematants from cells treated with oligonucleotides or culture medium for 24 h 
were collected and assayed for TGF-fl by the CCL64 bioassay (Khalil et al., 1989). The TGF-fl levels were determined from four indepen- 
dent cultures in two experiments. 
fl, by C3 cells (Schwartz et al.,  1990).  This was tested by 
treating  C3  cells,  after  24  h  in  culture,  with  the  anti- 
RHAMM fusion protein antibody in the absence of added 
TGF-fl~.  Within  2  h  of addition  of antibody,  the  rate  of 
locomotion decreased significantly from 24.5  +  3.1  to 7.5 
-t-  1.3  #m/min indicating  that spontaneous locomotion of 
these cells could be blocked by an antibody that interferes 
with HA/RHAMM interaction. 
Inhibition of TGF-fl-Induced  and Spontaneous 
l~brosarcoma Motility by Peptide  ~2~2  from the 
Hyaluronan-Binding Domain of  RHAMM 
RHAMM contains two discrete HA binding domains located 
near the carboxyl terminus characterized by clusters of basic 
amino acids (Yang et al.,  1993). Pcptides mimicking either 
of the two domains inhibit HA binding to RHAMM (Yang 
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Figure 8.  Anti-RHAMM  monoclonal  and  polyclonal  antibodies 
block TGF-flt induced locomotion.  C3 cells were stimulated with 
10 ng/ml TGF-fll for 8 h in the presence or absence of antibodies. 
Monoclonal anti-RHAMM antibodies MSV  10-4 and MSV 10-6 
are compared to normal murine IgG. Rabbit antibody to RHAMM 
peptide 26s-28s and  anti-RHAMM  fusion  protein  antibody,  which 
have been shown to block HA-induced locomotion, were compared 
to anti-RHAMM peptidC 2.~45 polyclonal antibody that is inactive 
(Hardwick et al.,  1992). 
et al., 1993). We have tested the hypothesis that peptide cor- 
responding  to  amino  acid  42a-432 of  RHAMM  will  block 
TGF-fl~-induced and spontaneous motility of the C3 fibro- 
sarcoma, presumably by interfering with the ability of HA 
to bind RHAMM. C3 cells were cultured, at subconfluence 
as described in Materials and Methods,  in the presence or 
absence of 10 ng/ml of TGF-fl~. At the initiation of the cul- 
ture,  either peptide  =~23-4a2, or  scrambled peptide  controls, 
was added at  10 #g/ml.  Complete abrogation of TGF-fl~- 
induced cell migration by RHAMM binding domain peptide, 
but not the scrambled peptide, was observed over a tracking 
period of 8 h (Fig. 9). Spontaneous locomotion of C3 cells 
was also suppressed by the peptide mimicking the HA bind- 
ing domain.  Cell locomotion increased from 10.8/zm/min 
seen at the initiation of the culture to 28.3 #m/min after 24 
h  of  culture  and  was  inhibited  to  14.7  #m/min  by  the 
RHAMM peptide (Fig.  9).  The scrambled peptide had no 
effect on spontaneous tumor locomotion. 
Discussion 
The evidence presented supports the hypothesis that the par- 
ticipation  of the  HA  receptor  RHAMM  is  necessary  for 
TGF-fll-mediated locomotion.  The addition  of TGF-fll to 
cell  cultures,  or  induction  of TGF-fll  secretion,  rapidly 
stimulated the synthesis of RHAMM message and protein, 
surface  expression  of RHAMM,  HA  synthesis,  and  cell 
locomotion. Antibodies that inhibited HA/RI-IAMM signal- 
ling  and  peptides  that  blocked  HA binding  to  RHAMM 
prevented TGF-fll-induced increases in the rate of locomo- 
tion, and the spontaneous locomotion of these cells. Further- 
more, blocking experiments with  either neutralizing  anti- 
TGF-fl antibody  or antisense  oligonucleotides  to  TGF-fll 
decreased cell locomotion indicating  that TGF-fl~ was es- 
sential  for  spontaneous  fibrosarcoma cell  motility.  From 
these data,  we hypothesize that TGF-fl~-induced locomo- 
tion requires the participation of the HA receptor RHAMM. 
TGF-flt likely activates the RHAMM receptor through in- 
creased synthesis of HA since peptides and antibodies that 
interfere with  HA binding to RHAMM blocked TGF-flm- 
induced  motility.  Additional  evidence that RHAMM may 
directly control cell motility comes from the recent analysis 
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tion by peptides mimicking the HA-binding  domains of RHAMM. 
(,4) C3 fibrosarcoma cells were cultured at subconfluenee in the 
presence of 10 ng/ml of TGF-/31 (11). Peptide  ~423-432 K-L-R-S-Q-L- 
V-K-R-K (A) corresponding to the second HA-binding domain of 
RI-IAMM (Yang  et al., 1993), or the scrambled sequence Q-S-K-R- 
L-K-K-R-V-L (.) was added to the cultures at a concentration of 
10 ~g/ml with the TGF-BI, and cell locomotion was analyzed ev- 
ery 2 h. (B) C3 cells were cultured in the absence of TGF-/3~. The 
cells were tracked for 2 h at the initiation of the culture (0 h) and 
between 22 and 24 h of culture (24 h).  Then, either peptide (left) 
or scrambled peptide (right) was added to the culture and the motil- 
ity rate analyzed for 2 h. 
of fibroblasts transfected with a genomic clone of RHAMM. 
These cells showed both enhanced membrane expression of 
the receptor and an increased cell locomotion rate (Yang, B., 
G. Curpen, C. Wong, A. H. Greenberg, and E. A. Turley, 
manuscript submitted for publication). 
The initial stimulation of motility by TGF-/3 was closely 
tied to increased levels of RHAMM mRNA and protein, and 
expression of RHAMM at the cell surface. Furthermore, a 
decrease in locomotion observed at TGF-/3, concentrations 
of 30 ng/ml or greater, was associated with lower RHAMM 
protein synthesis suggesting that down-regulation of cell mo- 
tility was linked to the decreased availability of RHAMM. 
However, this may not be the only way in which locomotory 
responses to TGF-/~ can be down-regulated as a progres- 
sive decline in locomotion was observed after prolonged 
(>24 h) TGF-131 stimulation in the presence of stable or in- 
creasing RHAMM expression (Fig.  2  B).  The decline in 
locomotion rate may come from either rapid neutralization 
of TGF-~1 in tissue culture, or from other actions of TGF- 
~1 that may suppress cell movement. 
TGF-jS, stimulates HA synthesis, and HA accumulates in 
the extending lamellae of locomoting tumor cells and can 
directly promote locomotion (Turley et al., 1991). However, 
TGF-~ induces the synthesis of other proteoglycans includ- 
ing chondroitin/dermatan sulfate (Chert et al., 1987; Bassols 
and Massagu6, 1988), heparan sulfate (Nugant et al., 1992), 
as well as biglycan and versican (Kahari et al., 1991). TGF-~ 
is inactivated by binding to the proteoglycan decorin (Yama- 
guchi et al.,  1990).  Since TGF-~ reduces the synthesis of 
decorin in fibroblasts (ICAhari  et al., 1991) it is unlikely that 
decorin is inactivating TGF4t, and modulating the locomo- 
tory  response.  Glycosaminoglycans such  as  chondroitin/ 
dermatan sulfate and heparan sulfate along with HA are im- 
portant modulators of cellular recognition, adhesion, and 
motility (H66k et al., 1984).  The possibility therefore exists 
that proteoglycans induced by TGF-~, other than HA, par- 
ticipate  in  the  locomotory response  either  indirectly by 
affecting adhesion, or directly by interfering with HA inter- 
action with RHAMM. Recent data indicate that heparan sul- 
fate binds with high affinity to the RHAMM receptor and 
effectively inhibits HA-binding and locomotion (Yang, B., 
and E. A. Turley, manuscript submitted for publication) con- 
sistent with other reports that heparan sulphate inhibits cell 
motility (Klein-Soyer et al., 1989).  Thus, TGF-/3~ may ulti- 
mately downregulate motility by inducing heparan sulfate 
synthesis. 
TGF-/3 also regulates the expression of the heterodimeric 
extracellular matrix integrin receptors (Heino et al.,  1989) 
that have been implicated in the control of cell adhesion and 
locomotion (Hynes, 1992). In fibroblasts and fibrosarcomas, 
as well as other cell types, TGF-/31 enhances the expression 
of the ~  integrin subunit and several a  integrin subunits 
(Heino et al.,  1989).  By substituting intracelhlar domains 
of different ot  subunits,  Chan et  al.  (1992)  have recently 
shown that the a4 integrin was important for rhabdomyosar- 
coma cell migration. Migration on various extracellular ma- 
trices can be blocked by antibodies to the/~ subunit, while 
antibodies  and  peptides  for  different ot  subunits blocked 
migration on certain types of matrix substrates (Yamada et 
al.,  1990).  Because the integrin receptors are important in 
cellular interaction with extracellular matrix and in focal 
adhesion formation, TGF-/~-induced increases in expression 
likely effect locomotion, although this has not been demon- 
strated directly. How the RKAMM and integrin receptors 
might interact to achieve the coordinated responses of se- 
quential adhesion and deadhesion that cells require to loco- 
mote is not known. 
Although HA  may promote  locomotion by  interacting 
with cell surface receptors (Toole,  1990;  Turley,  1992),  it 
also binds to a number of proteins that are extracellular such 
as link protein (Goetinck et al., 1987; Nearne et al., 1986), 
versican (Krusius et al., 1987),  hyaluronectin (Delpech and 
Halavent, 1981; Perides et al., 1989),  and aggrecan (Doege 
et al., 1987).  Once HA secretion is stimulated by TGF-/3, it 
may interact  with the  extracellular binding proteins  that 
could  enhance  or  inhibit  its  interaction with  membrane 
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face receptor is CD44.  One isoform,  CD44H,  binds HA 
while  the  CD44E  isoform  does  not  (Culty  et  ai.,  1990; 
Stamenkovic et ai.,  1989).  CD44H but not CD44E,  when 
expressed in melanoma cells, increased migration on HA- 
coated substrate  (Thomas et al.,  1992).  Although this sug- 
gests a role for CD44 in cell locomotion, it is not clear what 
is the relative contribution of CD44  and RHAMM  to the 
locomotory response. It is possible that both HA receptors 
are required but may have different functions in adhesion and 
locomotion. However, at this point we only have evidence to 
suggest  that  RHAMM  participates  in the  TGF-B-induced 
locomotory response. 
Many human and animal tumors secrete elevated levels of 
TGF-B or have increased mRNA or protein expression (An- 
zano et al.,  1985;  Dalai et ai.,  1993; Derynck et ai.,  1987; 
Schwarz  et  ai.,  1990),  and  in  human  and  experimental 
tumors,  TGF-/~I is detected at high levels in metastases  in 
vitro and in vivo (Dalai et al.,  1993;  Schwarz et ai.,  1990; 
Perotti et ai.,  1991).  Tumors that are highly metastatic are 
also often highly motile (Paratin et al.,  1988,  1989).  TGF- 
B~ has been found to stimulate the motility and invasion of 
tumors of both mesenchymai and epithelial origin such as 
murine fibrosarcoma (Samuel et al.,  1992), human pulmo- 
nary adenocarcinoma (Mooradian et ai., 1992), and murine 
breast carcinoma (Welsh et al., 1991).  Our observation that 
the  spontaneous  motility  of  fibrosarcoma  cells  can  be 
blocked by  inhibiting  "I'GF-/~I synthesis  or neutralizing its 
activity following secretion is direct evidence that the motil- 
ity of malignant fibrosarcoma cells may be regulated through 
the production of TGF-/3. 
TGF-/3 is only one of many cytokines that promote motil- 
ity, and it does not promote motility in all cell types. Loco- 
motion of some cells, such as those of endothelial origin, is 
suppressed by TGF-/3 but is enhanced by bFGF (Sato and 
Rifkin,  1988;  Madri  et al.,  1988).  The FGF  family, IGF, 
PDGF family, TGF-t~, TNF-ot, CSF family, IL-8, and inter- 
ferons, in addition to complement and some matrix proteins, 
induce locomotion of many normal and transformed cells of 
epithelial and mesenchymal  origin (as reviewed in Stoker 
and  Gherardi,  1991).  It  is  therefore  likely  that  these 
cytokines are also used to promote locomotion by autocrine 
or paracrine stimulation, similar to TGF-B. Recent evidence 
from this laboratory suggests that macrophage chemotaxis 
induced by endotoxin activated  serum (C5a), as well as IL- 
8-induced neutrophil chemotaxis, are inhibited by blocking 
HA/RHAMM  interaction (Shi,  Y.,  R.  Savani,  and E.  A. 
Turley,  manuscript in preparation).  It remains to be  seen 
whether the RHAMM receptor will also be utilized in other 
types of cytokine-induced motility. 
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